(Q35087481)

6 August 2017

1 reference

title

Lipid abnormalities in the metabolic syndrome (English)

1 reference

6 August 2017

1 reference

Eliot A Brinton

1

1 reference

6 August 2017

publication date

1 February 2003

1 reference

6 August 2017

published in

Current diabetes report

1 reference

6 August 2017

volume

3

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

65-72

1 reference

https://scigraph.springernature.com/pub.10.1007/s11892-003-0056-3

6 August 2017

exact match

0 references

cites work

Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS).

1 reference

https://api.crossref.org/works/10.1007%2FS11892-003-0056-3

Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-003-0056-3

Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-003-0056-3

The triglyceride issue revisited. Findings from the Helsinki Heart Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-003-0056-3

Relation of LDL size to the insulin resistance syndrome and coronary heart disease in American Indians. The Strong Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-003-0056-3

Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-003-0056-3

Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investiga

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-003-0056-3

Insulin and Cardiovascular Disease: Paris Prospective Study

21 January 2018

1 reference

12 December 2020

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

1 reference

12 December 2020

Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study

1 reference

12 December 2020

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

12 December 2020

Cardiovascular morbidity and mortality associated with the metabolic syndrome

1 reference

12 December 2020

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

1 reference

12 December 2020

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

12 December 2020

Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study

1 reference

12 December 2020

Management of dyslipidemia in NIDDM.

1 reference

12 December 2020

Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study.

1 reference

12 December 2020

Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes

1 reference

12 December 2020

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

12 December 2020

Diabetes and all-cause and coronary heart disease mortality among US male physicians

1 reference

12 December 2020

Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.

1 reference

12 December 2020

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

1 reference

12 December 2020

A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis

1 reference

12 December 2020

Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial

1 reference

12 December 2020

Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

1 reference

12 December 2020

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

12 December 2020

Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: predictive role of C-reactive protein.

1 reference

12 December 2020

A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction

1 reference

12 December 2020

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S.

1 reference

12 December 2020

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

12 December 2020

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

12 December 2020

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

1 reference

12 December 2020

The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations

1 reference

12 December 2020

Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

12 December 2020

Abdominal adiposity and coronary heart disease in women

1 reference

12 December 2020

Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus

1 reference

12 December 2020

Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study

1 reference

12 December 2020

Adverse effects of diabetes on multiple cardiovascular disease risk factors in women. The Strong Heart Study

1 reference

12 December 2020

Blood-sugar and arterial disease

1 reference

12 December 2020

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

12 December 2020

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Diabetes and cardiovascular disease. The Framingham study

1 reference

12 December 2020

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

1 reference

12 December 2020

Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus: a meta-analysis

1 reference

12 December 2020

Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial

1 reference

12 December 2020

Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance.

1 reference

12 December 2020

Diabetes and decline in heart disease mortality in US adults.

1 reference

12 December 2020

10.1007/S11892-003-0056-3

Identifiers

DOI

1 reference

6 August 2017

1 reference